EUVIMEDEUVIMED entdecken
Crossref

Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes

Bao-Ngoc Nguyen iD, Shweta Mital, Shawn Bugden, Hai V Nguyen

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Bao-Ngoc Nguyen und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To examine the cost‐effectiveness of adding canagliflozin or dapagliflozin to standard of care (SoC) versus SoC alone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Materials and Methods We used a Markov microsimulation model to assess the cost‐effectiveness of canagliflozin plus SoC (canagliflozin + SoC), dapagliflozin plus SoC (dapagliflozin + SoC) and SoC alone. Analyses were conducted from a healthcare system perspective. Costs were measured in 2021 Canadian dollars (C$), and effectiveness was measured in quality‐adjusted life‐years (QALYs).

Results

Over a patient's lifetime, canagliflozin + SoC and dapagliflozin + SoC yielded cost savings of C$33 460 and C$26 764 and generated 1.38 and 1.44 additional QALYs compared with SoC alone, respectively. While QALY gains with dapagliflozin + SoC were higher than those with canagliflozin + SoC, this strategy was also more costly with the incremental cost‐effectiveness ratio exceeding the willingness to pay threshold of C$50 000 per QALY. Dapagliflozin + SoC, however, generated cost savings and QALY gains compared with canagliflozin + SoC over shorter time horizons of 5 or 10 years.

Conclusions

Dapagliflozin + SoC was not cost‐effective versus canagliflozin + SoC in patients with CKD and T2D over the lifetime horizon. However, adding canagliflozin or dapagliflozin to SoC was less costly and more effective relative to SoC alone for treatment of CKD and T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicHumansHypoglycemic AgentsCanagliflozinCost-Benefit AnalysisDrug Therapy, CombinationCanadaQuality-Adjusted Life YearsBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

canagliflozinchronic kidney diseasecost-effectivenessdapagliflozintype 2 diabetes

Substanzen

Hypoglycemic AgentsCanagliflozindapagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
  • College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada.

ORCID-Profile: Bao-Ngoc Nguyen

Zitieren

APA

Nguyen, B. N., Mital, S., Bugden, S., & Nguyen, H. V. (2023). Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15201

Vancouver

Nguyen BN, Mital S, Bugden S, Nguyen HV. Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15201

BibTeX
@article{Nguyen2023,
  author = {Nguyen, Bao-Ngoc and Mital, Shweta and Bugden, Shawn and Nguyen, Hai V},
  title = {Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15201}
}
Kostenlos starten →